Use of RAAS Inhibitors and Risk of Clinical Deterioration in COVID-19: Results From an Italian Cohort of 133 Hypertensives

The effect of chronic use of renin-angiotensin-aldosterone system (RAAS) inhibitors on the severity of COVID-19 infection is still unclear in patients with hypertension. We aimed to investigate the association between chronic use of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:American journal of hypertension Ročník 33; číslo 10; s. 944
Hlavní autori: Felice, Carla, Nardin, Chiara, Di Tanna, Gian Luca, Grossi, Ugo, Bernardi, Enrico, Scaldaferri, Luca, Romagnoli, Micaela, Tonon, Luca, Cavasin, Paola, Novello, Simone, Scarpa, Riccardo, Farnia, Antonio, De Menis, Ernesto, Rigoli, Roberto, Cinetto, Francesco, Pauletto, Paolo, Agostini, Carlo, Rattazzi, Marcello
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: 21.10.2020
ISSN:1941-7225, 1941-7225
On-line prístup:Zistit podrobnosti o prístupe
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Abstract The effect of chronic use of renin-angiotensin-aldosterone system (RAAS) inhibitors on the severity of COVID-19 infection is still unclear in patients with hypertension. We aimed to investigate the association between chronic use of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) and COVID-19-related outcomes in hypertensive patients.BACKGROUNDThe effect of chronic use of renin-angiotensin-aldosterone system (RAAS) inhibitors on the severity of COVID-19 infection is still unclear in patients with hypertension. We aimed to investigate the association between chronic use of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) and COVID-19-related outcomes in hypertensive patients.A single-center study was conducted on 133 consecutive hypertensive subjects presenting to the emergency department with acute respiratory symptoms and/or fever who were diagnosed with COVID-19 infection between 9 and 31 March 2020.METHODSA single-center study was conducted on 133 consecutive hypertensive subjects presenting to the emergency department with acute respiratory symptoms and/or fever who were diagnosed with COVID-19 infection between 9 and 31 March 2020.All patients were grouped according to their chronic antihypertensive medications (ACEIs, N = 40; ARBs, N = 42; not on RAAS inhibitors, N = 51). There was no statistical difference between ACEIs and ARBs groups in terms of hospital admission rate, oxygen therapy, and need for noninvasive ventilation. Patients chronically treated with RAAS inhibitors showed a significantly lower rate of admission to semi-intensive/intensive care units, when compared with the non-RAAS population (odds ratio (OR) 0.25, confidence interval (CI) 95% 0.09-0.66, P = 0.006). Similarly, the risk of mortality was lower in the former group, although not reaching statistical significance (OR 0.56, CI 95% 0.17-1.83, P = 0.341).RESULTSAll patients were grouped according to their chronic antihypertensive medications (ACEIs, N = 40; ARBs, N = 42; not on RAAS inhibitors, N = 51). There was no statistical difference between ACEIs and ARBs groups in terms of hospital admission rate, oxygen therapy, and need for noninvasive ventilation. Patients chronically treated with RAAS inhibitors showed a significantly lower rate of admission to semi-intensive/intensive care units, when compared with the non-RAAS population (odds ratio (OR) 0.25, confidence interval (CI) 95% 0.09-0.66, P = 0.006). Similarly, the risk of mortality was lower in the former group, although not reaching statistical significance (OR 0.56, CI 95% 0.17-1.83, P = 0.341).Our data suggest that chronic use of RAAS inhibitors does not negatively affect clinical course of COVID-19 in hypertensive patients. Further studies are needed to confirm this finding and determine whether RAAS inhibitors may have a protective effect on COVID-19-related morbidity and mortality.CONCLUSIONSOur data suggest that chronic use of RAAS inhibitors does not negatively affect clinical course of COVID-19 in hypertensive patients. Further studies are needed to confirm this finding and determine whether RAAS inhibitors may have a protective effect on COVID-19-related morbidity and mortality.
AbstractList The effect of chronic use of renin-angiotensin-aldosterone system (RAAS) inhibitors on the severity of COVID-19 infection is still unclear in patients with hypertension. We aimed to investigate the association between chronic use of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) and COVID-19-related outcomes in hypertensive patients.BACKGROUNDThe effect of chronic use of renin-angiotensin-aldosterone system (RAAS) inhibitors on the severity of COVID-19 infection is still unclear in patients with hypertension. We aimed to investigate the association between chronic use of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) and COVID-19-related outcomes in hypertensive patients.A single-center study was conducted on 133 consecutive hypertensive subjects presenting to the emergency department with acute respiratory symptoms and/or fever who were diagnosed with COVID-19 infection between 9 and 31 March 2020.METHODSA single-center study was conducted on 133 consecutive hypertensive subjects presenting to the emergency department with acute respiratory symptoms and/or fever who were diagnosed with COVID-19 infection between 9 and 31 March 2020.All patients were grouped according to their chronic antihypertensive medications (ACEIs, N = 40; ARBs, N = 42; not on RAAS inhibitors, N = 51). There was no statistical difference between ACEIs and ARBs groups in terms of hospital admission rate, oxygen therapy, and need for noninvasive ventilation. Patients chronically treated with RAAS inhibitors showed a significantly lower rate of admission to semi-intensive/intensive care units, when compared with the non-RAAS population (odds ratio (OR) 0.25, confidence interval (CI) 95% 0.09-0.66, P = 0.006). Similarly, the risk of mortality was lower in the former group, although not reaching statistical significance (OR 0.56, CI 95% 0.17-1.83, P = 0.341).RESULTSAll patients were grouped according to their chronic antihypertensive medications (ACEIs, N = 40; ARBs, N = 42; not on RAAS inhibitors, N = 51). There was no statistical difference between ACEIs and ARBs groups in terms of hospital admission rate, oxygen therapy, and need for noninvasive ventilation. Patients chronically treated with RAAS inhibitors showed a significantly lower rate of admission to semi-intensive/intensive care units, when compared with the non-RAAS population (odds ratio (OR) 0.25, confidence interval (CI) 95% 0.09-0.66, P = 0.006). Similarly, the risk of mortality was lower in the former group, although not reaching statistical significance (OR 0.56, CI 95% 0.17-1.83, P = 0.341).Our data suggest that chronic use of RAAS inhibitors does not negatively affect clinical course of COVID-19 in hypertensive patients. Further studies are needed to confirm this finding and determine whether RAAS inhibitors may have a protective effect on COVID-19-related morbidity and mortality.CONCLUSIONSOur data suggest that chronic use of RAAS inhibitors does not negatively affect clinical course of COVID-19 in hypertensive patients. Further studies are needed to confirm this finding and determine whether RAAS inhibitors may have a protective effect on COVID-19-related morbidity and mortality.
Author Rigoli, Roberto
Di Tanna, Gian Luca
Nardin, Chiara
Rattazzi, Marcello
Farnia, Antonio
De Menis, Ernesto
Felice, Carla
Pauletto, Paolo
Scarpa, Riccardo
Grossi, Ugo
Cinetto, Francesco
Agostini, Carlo
Bernardi, Enrico
Romagnoli, Micaela
Novello, Simone
Tonon, Luca
Scaldaferri, Luca
Cavasin, Paola
Author_xml – sequence: 1
  givenname: Carla
  surname: Felice
  fullname: Felice, Carla
– sequence: 2
  givenname: Chiara
  surname: Nardin
  fullname: Nardin, Chiara
– sequence: 3
  givenname: Gian Luca
  surname: Di Tanna
  fullname: Di Tanna, Gian Luca
– sequence: 4
  givenname: Ugo
  surname: Grossi
  fullname: Grossi, Ugo
– sequence: 5
  givenname: Enrico
  surname: Bernardi
  fullname: Bernardi, Enrico
– sequence: 6
  givenname: Luca
  surname: Scaldaferri
  fullname: Scaldaferri, Luca
– sequence: 7
  givenname: Micaela
  surname: Romagnoli
  fullname: Romagnoli, Micaela
– sequence: 8
  givenname: Luca
  surname: Tonon
  fullname: Tonon, Luca
– sequence: 9
  givenname: Paola
  surname: Cavasin
  fullname: Cavasin, Paola
– sequence: 10
  givenname: Simone
  surname: Novello
  fullname: Novello, Simone
– sequence: 11
  givenname: Riccardo
  surname: Scarpa
  fullname: Scarpa, Riccardo
– sequence: 12
  givenname: Antonio
  surname: Farnia
  fullname: Farnia, Antonio
– sequence: 13
  givenname: Ernesto
  surname: De Menis
  fullname: De Menis, Ernesto
– sequence: 14
  givenname: Roberto
  surname: Rigoli
  fullname: Rigoli, Roberto
– sequence: 15
  givenname: Francesco
  surname: Cinetto
  fullname: Cinetto, Francesco
– sequence: 16
  givenname: Paolo
  surname: Pauletto
  fullname: Pauletto, Paolo
– sequence: 17
  givenname: Carlo
  surname: Agostini
  fullname: Agostini, Carlo
– sequence: 18
  givenname: Marcello
  surname: Rattazzi
  fullname: Rattazzi, Marcello
BookMark eNpNjM1OAjEURhujiYCufIEu3Yzcdjo_dUcGkUlISFDcks5wmymWFqfFRJ9eiC5cnZN8-c6QXDrvkJA7Bg8MZDpWu27cHZQCmV-QAZOCJQXn2eU_vybDEHYAIPKcDcj3OiD1mq4mkxdau840Jvo-UOW2dGXC-3mrrHGmVZZOMWJvfK-i8Y4aR6vlWz1NmHykKwxHGwOd9X5_OtM6KmtOrHzn-3iusDSl868D9hFdMJ8YbsiVVjbg7R9HZD17eq3myWL5XFeTRdIKLmLCG9VmkJ8cWpWBQs41pKXIUOdNIZXgbZmVEjQvirKRUELeotS63OpUYCP4iNz_dg-9_zhiiJu9CS1aqxz6Y9hwwRgDJiHlPyXKYT8
CitedBy_id crossref_primary_10_1155_2020_1025913
crossref_primary_10_1055_s_0040_1715798
crossref_primary_10_1111_bcp_14660
crossref_primary_10_3390_diagnostics10080548
crossref_primary_10_3390_jcm9082506
crossref_primary_10_1371_journal_pone_0275787
crossref_primary_10_1016_j_bcp_2022_115370
crossref_primary_10_1136_thoraxjnl_2020_215768
crossref_primary_10_1016_j_amjcard_2021_12_004
crossref_primary_10_1097_CCM_0000000000005627
crossref_primary_10_1177_20420986211011345
crossref_primary_10_7326_L20_0969
crossref_primary_10_1161_JAHA_122_025289
crossref_primary_10_1186_s13643_021_01802_6
crossref_primary_10_3390_ijms232214340
crossref_primary_10_1093_ajh_hpaa169
crossref_primary_10_1001_jamanetworkopen_2021_3594
crossref_primary_10_1097_HJH_0000000000002784
crossref_primary_10_1007_s40292_021_00462_w
crossref_primary_10_1016_j_jjcc_2020_07_013
crossref_primary_10_1002_jmv_26695
crossref_primary_10_1016_j_cjco_2021_03_001
crossref_primary_10_1016_j_acvd_2020_09_002
crossref_primary_10_1016_j_medcli_2021_04_005
crossref_primary_10_1007_s12471_021_01573_8
crossref_primary_10_1186_s12879_021_06088_6
crossref_primary_10_1161_JAHA_120_021154
crossref_primary_10_3389_fcvm_2021_609857
crossref_primary_10_1093_cid_ciaa1443
crossref_primary_10_6061_clinics_2021_e2342
crossref_primary_10_1097_HJH_0000000000003266
crossref_primary_10_1007_s40256_020_00439_5
crossref_primary_10_3389_fmed_2021_703661
crossref_primary_10_1016_j_jjcc_2020_10_015
crossref_primary_10_1007_s13410_022_01143_7
crossref_primary_10_1186_s12985_021_01526_y
crossref_primary_10_3389_fendo_2023_1077959
crossref_primary_10_1111_jch_14329
crossref_primary_10_1136_bmjopen_2020_043625
crossref_primary_10_1080_10641963_2021_1963070
crossref_primary_10_1093_ajh_hpaa149
crossref_primary_10_1007_s11906_022_01207_3
crossref_primary_10_1038_s41440_024_01953_8
crossref_primary_10_1093_ajh_hpac001
crossref_primary_10_1097_MD_0000000000025532
crossref_primary_10_1186_s43044_022_00303_8
crossref_primary_10_1016_j_medcle_2021_04_026
crossref_primary_10_1002_jmv_26625
crossref_primary_10_1016_j_jiph_2021_03_004
crossref_primary_10_3390_arm93010004
crossref_primary_10_7326_L20_1446
crossref_primary_10_3390_ph15060739
crossref_primary_10_3390_jcm10245812
crossref_primary_10_1007_s11906_021_01134_9
crossref_primary_10_3389_fphys_2021_624052
ContentType Journal Article
Copyright American Journal of Hypertension, Ltd 2020. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
Copyright_xml – notice: American Journal of Hypertension, Ltd 2020. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
DBID 7X8
DOI 10.1093/ajh/hpaa096
DatabaseName MEDLINE - Academic
DatabaseTitle MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
Database_xml – sequence: 1
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Medicine
EISSN 1941-7225
GroupedDBID ---
.2P
.I3
.ZR
0R~
23M
39C
4.4
48X
53G
5GY
5RE
5WD
70F
7X8
AABZA
AACZT
AAFWJ
AAJKP
AAMVS
AAOGV
AAPQZ
AAPXW
AARHZ
AAUAY
AAUQX
AAVAP
ABDFA
ABEJV
ABEUO
ABGNP
ABIXL
ABJNI
ABKDP
ABNHQ
ABNKS
ABOCM
ABPQP
ABPTD
ABQLI
ABQNK
ABVGC
ABWST
ABXVV
ABZBJ
ACGFS
ACUFI
ACUTJ
ACUTO
ACYHN
ADBBV
ADEYI
ADGZP
ADHKW
ADHZD
ADIPN
ADNBA
ADOCK
ADQBN
ADRTK
ADVEK
ADYVW
ADZXQ
AEGPL
AEJOX
AEKSI
AEMDU
AEMQT
AENEX
AENZO
AEPUE
AETBJ
AEWNT
AFFZL
AFIYH
AFOFC
AFXAL
AFYAG
AGINJ
AGQXC
AGSYK
AGUTN
AHGBF
AHMBA
AHMMS
AHXPO
AJBYB
AJEEA
AJNCP
AKRWK
ALMA_UNASSIGNED_HOLDINGS
ALUQC
ALXQX
APIBT
ATGXG
AVWKF
AXUDD
BAYMD
BCRHZ
BEYMZ
BHONS
BTRTY
BVRKM
C45
CDBKE
CS3
DAKXR
DILTD
D~K
EBS
EE~
EMOBN
ENERS
F5P
F9B
FDB
FECEO
FLUFQ
FOEOM
FOTVD
FQBLK
G-Q
GAUVT
GJXCC
H13
H5~
HAR
HW0
HZ~
J21
JXSIZ
KBUDW
KOP
KSI
KSN
MHKGH
ML0
NGC
NOMLY
NOYVH
O9-
OAUYM
OAWHX
OCZFY
ODMLO
OJQWA
OJZSN
OPAEJ
OVD
OWPYF
O~Y
P2P
PAFKI
PEELM
Q1.
Q5Y
ROX
ROZ
RPZ
RUSNO
RW1
RXO
TEORI
TJX
WH7
YAYTL
YKOAZ
YXANX
ID FETCH-LOGICAL-c424t-2bac5064240ca50ae22f03845ef6b79a42c85890f2778b90806ce9ff8df34eb42
IEDL.DBID 7X8
ISICitedReferencesCount 61
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000592721900007&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1941-7225
IngestDate Wed Oct 01 14:16:14 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 10
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c424t-2bac5064240ca50ae22f03845ef6b79a42c85890f2778b90806ce9ff8df34eb42
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://academic.oup.com/ajh/article-pdf/33/10/944/46426729/hpaa096.pdf
PQID 2411101903
PQPubID 23479
ParticipantIDs proquest_miscellaneous_2411101903
PublicationCentury 2000
PublicationDate 20201021
PublicationDateYYYYMMDD 2020-10-21
PublicationDate_xml – month: 10
  year: 2020
  text: 20201021
  day: 21
PublicationDecade 2020
PublicationTitle American journal of hypertension
PublicationYear 2020
SSID ssj0004661
Score 2.5647514
Snippet The effect of chronic use of renin-angiotensin-aldosterone system (RAAS) inhibitors on the severity of COVID-19 infection is still unclear in patients with...
SourceID proquest
SourceType Aggregation Database
StartPage 944
Title Use of RAAS Inhibitors and Risk of Clinical Deterioration in COVID-19: Results From an Italian Cohort of 133 Hypertensives
URI https://www.proquest.com/docview/2411101903
Volume 33
WOSCitedRecordID wos000592721900007&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3JTsMwELWAIsSFHbHLSFytJo4bx1xQ1VLRAwWVRb0h27HVQEmgSTnw9YyDEUhckDhnUTSazHuzeB5CJ5QLzVIakUBzRpgWIZFUUhLGKk5Ta6TRqhab4INBMhqJa19wK_1Y5VdMrAN1WmhXI28C0gBSAXxFZy-vxKlGue6ql9CYR40IqIwb6eKjH9vC4899qYKFhIPj-vN5kMQ35eO4OX6RMhDxryhcQ0tv9b8ftYZWPKnE7U8vWEdzJt9AS5e-bb6J3u9KgwuLh-32De7n40xlTmQHyzzFw6x8ctf8gtAJ7roBmcx7Bs5y3Lm673dJKE7x0JSzSVXi3rR4hodxv6qrJLhTjIHFu7dALoovILWd-sH4cgvd9c5vOxfEiy4QzSirCFVSuyV2gPROLUEaSm0QJaxlbKy4kIzqpJWIwFLOEyWAcMbaCGuT1EbMKEa30UJe5GYHYWu5MioWCmzPUgYu0AIyoYAQaa6NTHbR8ZdVH8CpXadC5qaYlQ_fdt37wz37aJm6LBgQhYYHqGHhxzWHaFG_VVk5Pap94gORH8Cp
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Use+of+RAAS+Inhibitors+and+Risk+of+Clinical+Deterioration+in+COVID-19%3A+Results+From+an+Italian+Cohort+of+133+Hypertensives&rft.jtitle=American+journal+of+hypertension&rft.au=Felice%2C+Carla&rft.au=Nardin%2C+Chiara&rft.au=Di+Tanna%2C+Gian+Luca&rft.au=Grossi%2C+Ugo&rft.date=2020-10-21&rft.issn=1941-7225&rft.eissn=1941-7225&rft.volume=33&rft.issue=10&rft.spage=944&rft_id=info:doi/10.1093%2Fajh%2Fhpaa096&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1941-7225&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1941-7225&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1941-7225&client=summon